Display options
Cite
Wei Y. On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities. Pharmaceuticals (Basel). 2015;8(3):455-73doi: 10.3390/ph8030455.
Wei, Y. (2015). On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities. Pharmaceuticals (Basel, Switzerland), 8(3), 455-73. https://doi.org/10.3390/ph8030455
Wei, Yufeng. "On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities." Pharmaceuticals (Basel, Switzerland) vol. 8,3 (2015): 455-73. doi: https://doi.org/10.3390/ph8030455
Wei Y. On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities. Pharmaceuticals (Basel). 2015 Jul 31;8(3):455-73. doi: 10.3390/ph8030455. PMID: 26263999; PMCID: PMC4588177.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2015 Jul 31;8(3):455-73. doi: 10.3390/ph8030455.

On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities.

Pharmaceuticals (Basel, Switzerland)

Yufeng Wei

Affiliations

  1. Department of Chemistry, New Jersery City University, 2039 Kennedy Blvd, Jersey City, NJ 07305, USA. [email protected].
  2. Institute of NeuroImmune Pharmacology, Seton Hall University, 400 South Orange Ave, South Orange, NJ 07094, USA . [email protected].

PMID: 26263999 PMCID: PMC4588177 DOI: 10.3390/ph8030455

Abstract

Phosphoprotein enriched in astrocytes, 15 KDa (PEA-15), a ubiquitously expressed small protein in all mammals, is known for decades for its potent interactions with various protein partners along distinct biological pathways. Most notable interacting partners of PEA-15 include extracellular signal-regulated kinase 1 and 2 (ERK1/2) in the mitogen activated protein kinase (MAPK) pathway, the Fas-associated death domain (FADD) protein involving in the formation of the death-inducing signaling complex (DISC), and the phospholipase D1 (PLD1) affecting the insulin sensitivity. However, the actual cellular functions of PEA-15 are still mysterious, and the question why this protein is expressed in almost all cell and tissue types remains unanswered. Here we synthesize the most recent structural, biological, and clinical studies on PEA-15 with emphases on its anti-apoptotic, anti-proliferative, and anti-inflammative properties, and propose a converged protective role of PEA-15 that maintains the balance of death and survival in different cell types. Under conditions that this delicate balance is unsustainable, PEA-15 may become pathological and lead to various diseases, including cancers and diabetes. Targeting PEA-15 interactions, or the use of PEA-15 protein as therapeutics, may provide a wider window of opportunities to treat these diseases.

Keywords: MAP kinase; PEA-15; apoptosis; phosphorylation; protein-protein interaction

References

  1. J Neurosci. 1999 Oct 1;19(19):8244-51 - PubMed
  2. Cancer Lett. 2015 Jan 28;356(2 Pt B):374-81 - PubMed
  3. Vitam Horm. 2004;67:409-26 - PubMed
  4. J Biol Chem. 2002 Jul 12;277(28):25020-5 - PubMed
  5. Diabetes. 2001 Jun;50(6):1244-52 - PubMed
  6. Psychiatry Res. 2011 Jan 30;185(1-2):9-15 - PubMed
  7. J Biol Chem. 2008 Nov 7;283(45):30970-9 - PubMed
  8. Biochemistry. 2007 Aug 14;46(32):9187-98 - PubMed
  9. J Biol Chem. 2006 Feb 3;281(5):2960-8 - PubMed
  10. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 - PubMed
  11. Mol Biol Cell. 2000 Sep;11(9):2863-72 - PubMed
  12. J Natl Cancer Inst. 1993 Feb 3;85(3):235-40 - PubMed
  13. Mol Cancer Ther. 2013 Jun;12(6):1099-111 - PubMed
  14. Mol Cell Biol. 2009 Mar;29(5):1222-34 - PubMed
  15. Biochim Biophys Acta. 2012 Dec;1824(12):1382-93 - PubMed
  16. Biochemistry. 2011 May 31;50(21):4568-78 - PubMed
  17. J Cell Mol Med. 2012 Jul;16(7):1435-46 - PubMed
  18. Oncogene. 2012 Jul 26;31(30):3547-60 - PubMed
  19. Cancer Res. 2005 Aug 1;65(15):6668-75 - PubMed
  20. Nature. 2012 Jun 06;486(7401):80-4 - PubMed
  21. Hum Gene Ther. 2010 Sep;21(9):1067-76 - PubMed
  22. J Biol Chem. 2003 Aug 22;278(34):32367-72 - PubMed
  23. Cancer Lett. 2013 Jul 28;335(2):431-40 - PubMed
  24. Oncogene. 2008 Feb 14;27(8):1155-66 - PubMed
  25. Physiol Rev. 2009 Jul;89(3):1025-78 - PubMed
  26. EMBO J. 1998 Jul 15;17(14):3858-66 - PubMed
  27. Mol Cancer Ther. 2012 Sep;11(9):1915-24 - PubMed
  28. Nature. 2006 Oct 19;443(7113):796-802 - PubMed
  29. Biochem Pharmacol. 2003 Oct 15;66(8):1581-8 - PubMed
  30. FASEB J. 2010 Aug;24(8):2818-28 - PubMed
  31. Diabetologia. 2006 Dec;49(12):3058-66 - PubMed
  32. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19837-42 - PubMed
  33. Oncogenesis. 2012 Jul 16;1:e22 - PubMed
  34. Mol Cell Biol. 2004 Jun;24(11):5005-15 - PubMed
  35. Annu Rev Immunol. 2007;25:561-86 - PubMed
  36. J Neurochem. 1998 Sep;71(3):1307-14 - PubMed
  37. Clin Cancer Res. 2010 Mar 15;16(6):1802-11 - PubMed
  38. Pharmacol Ther. 2014 Sep;143(3):265-74 - PubMed
  39. Nat Commun. 2013;4:1681 - PubMed
  40. Mol Cell Biol. 2014 Jun;34(12):2264-82 - PubMed
  41. Biochem Biophys Res Commun. 2012 Jul 20;424(1):141-6 - PubMed
  42. FEBS Lett. 2005 Jun 13;579(15):3278-86 - PubMed
  43. Cell Death Differ. 2012 Jun;19(6):990-1002 - PubMed
  44. Mol Cell Biol. 2003 Jul;23(13):4511-21 - PubMed
  45. Leuk Res. 2009 Nov;33(11):1539-51 - PubMed
  46. J Neurochem. 1995 Mar;64(3):1016-25 - PubMed
  47. J Cell Physiol. 2014 Oct;229(10):1359-68 - PubMed
  48. Eur Neuropsychopharmacol. 2010 Jan;20(1):49-64 - PubMed
  49. Neuroscience. 2009 Jun 16;161(1):23-38 - PubMed
  50. J Biol Chem. 2000 Nov 10;275(45):35224-32 - PubMed
  51. Cancer Res. 2001 Feb 1;61(3):1162-70 - PubMed
  52. Biochem J. 2005 Sep 15;390(Pt 3):729-35 - PubMed
  53. Cancer Res. 2007 Feb 15;67(4):1536-44 - PubMed
  54. Oncogene. 1999 Aug 5;18(31):4409-15 - PubMed
  55. Chromosoma. 2005 Jul;114(2):86-91 - PubMed
  56. Med Sci Monit. 2004 Oct;10 (10 ):RA235-41 - PubMed
  57. Biochim Biophys Acta. 2014 Jun;1840(6):1686-700 - PubMed
  58. PLoS One. 2013 Dec 31;8(12):e83421 - PubMed
  59. Oncogene. 2006 Jan 5;25(1):79-90 - PubMed
  60. J Neurooncol. 2010 Dec;100(3):449-57 - PubMed
  61. Breast Cancer Res. 2014 Aug 06;16(4):420 - PubMed
  62. J Cell Mol Med. 2008 Dec;12(6A):2416-26 - PubMed
  63. Dev Cell. 2001 Aug;1(2):239-50 - PubMed
  64. Mol Cell. 2006 Jun 9;22(5):599-610 - PubMed
  65. Neuroscience. 2011 Nov 24;196 :1-15 - PubMed
  66. Neuroscience. 2004;126(2):263-75 - PubMed
  67. Mol Cell. 2005 Dec 22;20(6):939-49 - PubMed
  68. J Biol Chem. 1996 Jun 21;271(25):14800-6 - PubMed
  69. J Cell Physiol. 2012 May;227(5):2106-16 - PubMed
  70. Cell. 1997 Oct 31;91(3):325-34 - PubMed
  71. Mol Biol Cell. 2005 Aug;16(8):3552-61 - PubMed
  72. Neurosci Lett. 2010 Jun 21;477(2):66-71 - PubMed
  73. Mol Cancer Ther. 2012 Feb;11(2):360-9 - PubMed
  74. Mol Biol Cell. 2010 Feb 15;21(4):664-73 - PubMed
  75. Mol Biol Cell. 2006 Sep;17(9):3940-51 - PubMed
  76. EMBO J. 2002 Dec 2;21(23):6494-504 - PubMed
  77. Clin Cancer Res. 2010 Feb 1;16(3):1033-41 - PubMed
  78. Cancer Res. 2008 Nov 15;68(22):9302-10 - PubMed
  79. Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E592-601 - PubMed
  80. Biochim Biophys Acta. 2008 Aug;1783(8):1490-502 - PubMed
  81. J Biol Chem. 2008 Aug 1;283(31):21769-78 - PubMed
  82. J Biol Chem. 2010 Jul 9;285(28):21644-54 - PubMed
  83. J Biol Chem. 1993 Mar 15;268(8):5911-20 - PubMed
  84. Apoptosis. 2012 Dec;17(12):1247-57 - PubMed
  85. Onkologie. 2002 Dec;25(6):511-8 - PubMed
  86. Cell Mol Life Sci. 2009 Mar;66(5):814-30 - PubMed
  87. Biochim Biophys Acta. 2013 Aug;1834(8):1572-80 - PubMed
  88. FEBS Lett. 2015 Apr 13;589(9):1033-9 - PubMed
  89. Small GTPases. 2012 Jul-Sep;3(3):173-7 - PubMed
  90. Cell Signal. 2015 Jun;27(6):1102-9 - PubMed
  91. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84 - PubMed
  92. FEBS Lett. 2013 Aug 2;587(15):2448-54 - PubMed
  93. Mol Biosyst. 2010 Oct;6(10):2039-48 - PubMed

Publication Types

Grant support